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ABSTRACT
B3 is a tumor-reactive monoclonal antibody (in VIÂ»that binds to a
limited number of normal tissues. Immunotoxins made with B3 coupled
to either Pseudomonas exotoxin (PE) or recombinant forms of PK with
a deletion of the cell-binding domain (LysPE40) have been shown to
cause complete tumor regression in nude mice bearing a rapidly growing
A431 (L. H. Pai et al., Proc. Nati. Acad. Sci. USA, 88: 3358-3362,
1991) human epidermoid carcinoma. In this study we show that an
inuminoli>\in composed of mAb B3 when chemically coupled to LysPE40
(B3-I.ysPK40) led to complete regression of a slowly growing breast
cancer, MCF-7, in nude mice when given i.v. every other day for five
doses. mAb B3 coupled to native PE also produced significant regression
of the MCF-7 tumor. The reactivity of mAb B3 was evaluated using an
immunohistochemical method on the two responsive tumors, MCF-7 and
A431, and compared with a typical human colon carcinoma specimen
that has B3 antigen on its surface. The results showed that both A431
and MCF'-7 xenograft tumors have similar reactivity to B3 when com
pared with the human colon carcinoma specimen. To evaluate the toxicity
of B3-PE in primates, Cynomolgus monkeys received escalating doses of
B3-PE i.v. on Days 1, 3, and 5. Based on antibody localization studies
using frozen sections of normal human and monkey tissue, gastric,
trachea, and bladder mucosa! injury could have occurred. However, no
clinical signs of injury or histolÃ³gica!damage to these organs were seen
at the doses administered. Chemical hepatitis due to PE was transient
and well tolerated at doses up to 50 Me/kg for three doses. The lethal
dose was about 100 ÃŸg/kg,and the cause of death was liver necrosis, as
shown by necropsy. We conclude that mAb B3, when coupled to PE40
or PE, can produce strong antitumor activity in vivo. The similar level of
reactivity of the B3 antibody in our tumor models with a surgical specimen
of a human colon carcinoma and the toxicity study in monkeys indicate
that therapeutic doses of B3-PE and B3-LysPE40 can be delivered
without causing toxicity to normal organs that express B3 antigen.
Although both B3-PE and B3-LysPE40 have antitumor activity in nude
mice bearing a human xenograft, B3-LysPE40 is better tolerated and
should be further evaluated as a therapeutic agent for cancer patients.
INTRODUCTION
In the past few decades monoclonal antibodies against human
cancer-associated antigens have allowed specific tumor target
ing to be explored as a new therapeutic modality for cancer.
Radioactive nuclides, chemotherapeutic agents, and bacterial
or plant toxins coupled to monoclonal antibodies are presently
being tested in cancer patients (1-4).
Our laboratory has focused on immunotoxins made with
PE.' It is a M, 66,000 protein that kills cells by ADP ribosyla-
tion and inactivation of elongation factor 2 which causes the
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arrest of protein synthesis. PE is composed of three major
structural domains each with a different function (5,6). Domain
I is responsible for cell recognition; Domain II, for translocation
across the cell membrane; and Domain III, for the ADP-
ribosylation activity of the toxin. Recently, the last five amino
acids of the carboxyl terminus of Domain III have also been
shown to have a role in translocation (7). LysPE40 is a M,
40,000 recombinant form of PE that lacks the cell-binding
domain and has a chemically reactive lysine residue near the
amino terminus which facilitates coupling to antibodies.
We have recently described a murine monoclonal antibody,
termed B3, that is directed against a carbohydrate antigen of
the Le> family that is present on the surface of many human
carcinomas. Immunohistochemical studies of human carcino
mas show that 12 of 12 adenocarcinomas of the colon react
with mAb B3, and 75% of these react strongly and homogene
ously. Similar strong uniform reactivity was found in gastric (3
of 4) and esophageal (7 of 9) carcinomas. B3 also reacts strongly
with 65% of the breast carcinomas and 55% of the ovarian
carcinomas tested (8). Most recently, we found that 10 of 15
adenocarcinomas of the lung also react strongly and uniformly
with mAb B3.4 Immunotoxins made with monoclonal antibody
B3 and native PE or with LysPE40 have been shown to have
cytotoxic activity against human tumor cell lines that express
the B3 antigen on their surface. These immunotoxins were also
shown to cause complete tumor regression in nude mice bearing
a rapidly growing human epidermoid carcinoma, A431 (9). In
this study, we initially evaluated the antitumor activity of im
munotoxins B3-PE and B3-LysPE40 when administered to
nude mice bearing a slowly growing human breast carcinoma,
MCF-7. Both the MCF-7 tumor and the A431 tumor are
appropriate models of human cancer because the amount of B3
antigen on these tumors, as shown by the immunohistochemical
reactivity, is equal to or less than the amount of B3 antigen
that is present in many human carcinoma specimens tested.
We also evaluated the toxicity of B3-PE in monkeys. Because
the B3 antibody does not react with mouse tissues but does
react with the stomach, trachea, and bladder of humans and
monkeys with equal intensity (8), we administered B3-PE to
monkeys. At a dose of 50 Mg/kg that caused complete regression
of A431 tumors in mice (9), no damage to stomach, trachea, or
bladder was observed. Our data indicate that B3-PE and B3-
LysPE40 merit further evaluation as therapeutic agents for
cancer.
MATERIALS AND METHODS
Monoclonal Antibody B3. The properties of mAb B3 (IgGU) have
been previously described (8). The mAb used for these experiments was
purified from serum-free culture medium by ammonium sulfate precip
itation and chromatography on Mono Q and TSK-250 gel filtration
columns. Its purity was established by sodium dodecyl sulfate/poly-
acrylamide gel electrophoresis. Monoclonal antibody MOPC-21
(Sigma Chemical Co.) was used as control antibody in our experiments.
4 Unpublished data.
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It is also a IgGU mouse monoclonal antibody with no known reactivity
with mouse or human tissues.
Pseudomonas Exotoxin. PE, purified from the culture medium of
Pseudomonas aeruginosa, was purchased from Swiss Serum (Berne,
Switzerland).
Construction of Plasmid-expressing LysPE40. Fig. 1 shows the plas-
mid pJBSLl f+t used for the expression of LysPE40 in Escherichia
coli. pJBSLl carries a LysPE40 gene under control of a T7 promoter
and also contains a T7 transcriptional terminator and an f 1 phagc
origin. Earlier, for LysPE40 expression we used the plasmid pJY85L
in which the LysPE40 gene is preceded by an OmpA signal sequence.
OmpA is cleaved upon secretion of LysPE40, leaving a three-amino
acid extension Ala-Asn-Leu at the amino terminus of LysPE40 (10,
11). To construct pJBSLl f+t, a 180-base pair fragment was amplified
by PCR using two oligonucleotides and pJYSSL as the template. One
oligonucleotide was the same as the 5' end of DNA encoding for
LysPE40 and also contained an Nde\ site at the 5' end of the codon
for the first alanine. The other oligonucleotide was complementary to
the sequence in Domain II and contained a Sail site. The PCR-
amplified fragment was restricted by Nde\ and Sail and purified by
electrophoresis. After purification the PCR fragment was ligated with
a 4.8-kilobase pair dephosphorylated Nde\-SaI\ fragment of pVC 8 f+t.
pVC 8 f+t is a plasmid containing a gene for PE40 under the control
of T7 promoter.
Expression and Purification of LysPE40. BL21 (XDE3) cells were
transformed with the plasmid pJBSLl f+t. The cells were grown in
superbroth containing 100 Mg/m' of Ampicillin at 37Â°C.At an A65oof
1.0, cells were induced with 1 mivi isopropyl-B-D-thiogalactopyrano-
side. The cells were harvested l h later, and protein was localized as
described elsewhere (10). The periplasm was used as the source of
LysPE40 because most of the expressed protein was secreted into the
periplasm. After filtration through a 0.45-Mm filter, periplasm was
applied onto an 8-ml Q-Sepharose column. Proteins were eluted by a
linear gradient from 0 to 0.5 M NaCl in 0.02 M Tris-HCI (pH 7.4). The
fractions containing LysPE40, as determined by sodium dodecyl sul-
fate/polyacrylamide gel electrophoresis, were pooled and applied on a
Mono Q 10/10 fast protein liquid chromatography (FPLC, Pharmacia)
column. The recombinant protein was eluted using the same linear
gradient described for the Q-Sepharose column. Further purification
was achieved by gel filtration chromatography on a TSK 250 column.
The N-terminal sequence of LysPE40 was found to be Ala-Asn-Leu-
Ala-Glu-Glu-Ala-Phe-Lys-Gly-Gly-Ser-Leu.
Construction of Immunoconjugates. The antibody and toxin were
linked by a thioether bond. PE and LysPE40 were incubated with 3-
fold molar excess of succinimidyl-4-(jV-maleimidomethyl) cyclohexane-
1-carboxylate (Pierce Chemical Co., Rockford, IL) at room temperature
for 30 min. Monoclonal antibody B3 and MOPC-21 were incubated
with 2-iminothiolane hydrochloride (Pierce Chemical Co., Rockford,
IL) at 37Â°Cfor 1 h. Details of conjugation and purification methods
have been described elsewhere (9).
Protein Synthesis Assay. The cytotoxic activity of the immunotoxins
was evaluated in cultured tumor cell lines by measuring [3H]leucine
incorporation as previously described (9). The mean values of triplicates
were expressed as a percentage of controls that did not receive
immunotoxin.
LOÂ«.Regarding toxicity of B3-PE and B3-LysPE40 in mice, groups
of female BALB/c mice were given injections i.p. with escalating doses
of immunotoxin diluted in 200 p\ of PBS-HSA (0.2%). Animals were
observed for 72 h for toxicity and death. The LD50 is the dose of
immunotoxin that kills 50% of the animals in 48 h.
Antitumor Activity of B3-PE and B3-LysPE40 in Nude Mice Bearing
a Human Breast Carcinoma. Human MCF-7 cells were grown as sub
cutaneous tumors in female athymic nude mice. On Day 0 of each
experiment, subcutaneous tumors were surgically removed from carrier
mice and cut in pieces of approximately 1 mm in size. The tumor was
implanted in the right flank using a sterile trochar. A 17/3-estradiol
pellet (0.72 mg/pellet, 60-day release) from Innovative Research of
America, Toledo, OH, was placed in the posterior cervical region to
maintain tumor growth. Treatment of mice with B3-PE or B3-LysPE40
was started 13 to 15 days after tumor implantation, when the tumor
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Fig. 1. Expression plasmid for LysPE40. Amino acids are shown using single-
letter symbols. The numbers refer to the respective number of amino acid in native
PE.
had reached 5x5 mm in size (50 mm3). Control groups received
MOPC-PE, mAb B3, or PBS containing 0.2% HSA. Each treatment
group consisted of six to eight animals. Tumors were measured with a
caliper every 4 days, and the volume of the tumor was calculated by
using the following formula: tumor volume (mm3) = length x (width)2
X0.4.
Immunohistochemistry. A frozen sample from a human colon carci
noma specimen and a MCF-7 subcutaneous tumor resected from nude
mice 20 days after tumor implantation were cryostat sectioned and
processed for peroxidase immunohistochemistry as previously de
scribed (12). To minimize cross-reaction with endogenous mouse IgG
in the tumor transplant, the initial immunoreactive step utilized a B3-
PE conjugate, followed by rabbit anti-PE, than an anti-rabbit-horse
radish peroxidase conjugate.
Toxicity of B3-PE in Cynomolgus Monkeys. This study was per
formed at the Hazleton Laboratories (Vienna, VA), Department of
Toxicology, by principal scientist Dr. Dan W. Dalgard (HWA Project
421-158) from December 18, 1990, though March 11, 1991, under an
approved animal protocol. B3-PE was prepared at the Laboratory of
Molecular Biology, National Cancer Institute, NIH. Eight Cynomolgus
monkeys, 2 in each group, received 10, 30, 50, and 100 jÂ¿g/kgof B3-
PE i.v. on Days 1, 3, and 5. All monkeys were screened and were found
not to contain antibodies against PE in the serum prior to the study.
Animals were observed for morbidity and mortality after dosing for
toxic or pharmacological effects, body weight, appearance, neurological
changes, appetite, and changes in excreta. Blood samples were collected,
and the serum chemistries performed included SCOT, SGPT, alkaline
phosphatase, bilirubin, lactate dehydrogenase, total protein, albumin,
glucose, blood urea nitrogen, creatinine, electrolytes, and amylase.
Hematology included standard indices and platelet estimation. Urinal-
ysis and examination of the stool for the presence of occult blood were
performed. Necropsy was performed in the 2 animals in the 100-^g/kg
group.
Assay of Blood Levels of B3-PE in Monkeys. Blood samples were
collected 10 min after each dose on Days 1, 3, and 5. The level of the
immunotoxin was measured by bioassay in which serum samples were
incubated with A431 cells, and the ability of the serum sample to inhibit
protein synthesis was measured. A standard curve was made for each
immunotoxin.
RESULTS
Immunotoxins made from monoclonal antibody B3 have
been shown to be cytotoxic for various human cancer cell lines
that express the B3 antigen on their surface (9). B3-PE is a
potent immunotoxin active against human epidermoid carci
noma, A431, and breast carcinoma, MCF-7; the ID50 for inhi
bition of protein synthesis for these cell lines was consistently
between 0.1 and 0.5 ng/ml (9). B3-LysPE40 is also active
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Fig. 2. Effect of B3-PE on the growth of MCF-7 tumors in nude mice. Tumors
were implanted on Day 0 and treated with 0.25 (D), 1 (â€¢).or 1.5 jig (O) of B3-
PE i.v. on Days 15, 17, 19, and 21. The control group received MOPC-PE (â€¢).
Points, mean; bars, SD.
against these cell lines with ID50s between 1 and 4 ng/ml. This
10-fold decrease in toxicity is due to the absence of Domain I
which decreases cytotoxic activity but also decreases nonspecific
toxicity in animals. The cytotoxic effects of the immunotoxins
are specific because they are eliminated when excess antibody
is added (50 pg/m\). No competition was seen when an excess
of an irrelevant antibody (MOPC-21) was used. Both B3-PE
and B3-LysPE40 did not intoxicate cells that do not express
the B3 antigen when tested up to 500 ng/ml (9).
To determine the toxicity of B3-PE and B3-LysPE40 in mice,
increasing doses of immunotoxins were injected i.p. into
BALB/c mice. The LD50 of B3-PE was found to be 125 ^g/kg,
and that of B3-LysPE40, 6250 Mg/kg per single dose. No
detrimental effects were noted in the control group that received
PBS-HSA (0.2%).
The antitumor activity of B3-PE and B3-LysPE40 was tested
in an animal model of breast cancer using the transplantable
estrogen-dependent MCF-7 tumor. On Day 0 of each experi
ment, athymic female nude mice were implanted with MCF-7
tumors (~ 1 mm in size) removed from carrier mice. The tumor
was implanted in the right flank. A 170-estradioI pellet (0.72
mg/pellet, 60-day release) was also implanted to maintain tu
mor growth. Treatment of mice with B3-PE or B3-LysPE40
was started 13 to 15 days after tumor implantation, when the
tumor reached 5x5 mm in size (50 mm1). As shown in Fig. 2,
in animals that were given four doses of 1.5 Â¿igof B3-PE on
Days 15, 17, 19, and 21, a very significant antitumor effect was
evident; the tumor stopped growing, regressed substantially in
size, but then resumed growth 8 to 10 days later. In animals
treated with 0.5 and 1 Â¿/g,lesser effects were seen. Control
animals treated with MOPC-PE, B3, or PBS-HSA (0.2%) had
no antitumor activity and were sacrificed 1 mo later when the
tumor size achieved 1.0 x 1.0 cm in size.
Fig. 3 shows the effect of B3-LysPE40 on the growth of
MCF-7 tumors in nude mice at various dose levels. Animals
were treated every other day i.v., with the immunotoxin at dose
levels of 20, 50, and 75 /ig. Treatment was started on Day 13.
At a dose level of 75 Mg/injection, complete regression of the
tumor was observed, which lasted for more than 1 mo. Control
animals treated with PBS or mAb B3 alone were sacrificed after
4 wk when tumors had reached 1.0 x 1.0 cm in size.
To determine if tumors growing in B3-PE-treated mice failed
to fully respond because they had become "antigen-negative,"
tumor was removed from a mouse treated with 1.5 ng of B3-
PE. By immunohistochemistry, these tumor cells had a positive
pattern of reactivity with B3 that is similar to cells maintained
in tissue culture (results not shown). We conclude that the
failure of B3-PE to cure the MCF-7 tumor was not due to the
emergence of antigen-negative clones, but due to the presence
of antigen-positive cells which might have been killed if larger
amounts of immunotoxin could have been delivered to the
tumor.
To determine if the MCF-7 tumors represent a model that is
relevant for the treatment of human cancers, we examined the
reactivity of B3 with a MCF-7 tumor removed from a nude
mouse 20 days after tumor implantation and an A431 tumor
removed 10 days after implantation and compared their reac
tivity with that of a human colon carcinoma sample. Immuno-
histochemical studies showed that the colon tumor reacted with
a stronger intensity than did the MCF-7 or A431 tumor growing
in mice (Fig. 4). Therefore we conclude that the model is
relevant for the study of human cancers.
To determine whether the specific (monoclonal antibody B3
related) or the nonspecific (PE related) toxicities would be dose
limiting, B3-PE was administered to Cynomolgus monkeys. In
addition, we wished to determine the maximum tolerated dose
in primates. These issues were especially relevant because mon
key tissues react in a similar manner and intensity as do human
tissues with the B3 antibody (8). Eight Cynomolgus monkeys,
two in each group, received i.v. injections of B3-PE at dose
levels of 10, 30, 50, and 100 Mg/kg on Days 1, 3, and 5. No
major clinical abnormalities were noted in the animals that
received 10, 30, and 50 /ig/kg except transient loss of appetite
and mild weight loss (less than 8% of the initial body weight)
during the first week. Elevation of SCOT, SGPT, alkaline
phosphatase, and lÃ¡clatedehydrogenase occurred in all animals.
The magnitude of the enzyme elevation ranged from 3- to 15-
fold from the pretreatment level. Fig. 5 shows the SCOT,
SGPT, and alkaline phosphatase levels of one animal from each
group. Elevation occurred by Day 3, generally peaking by Day
5, and then returning to pretreatment values by the end of 2 wk
CO
E
u
N
W
l-
o
E
3
0.0
15 20 25 30 35 40 45 50 55
Time (days)
Fig. 3. Effect of B3-LysPE40 on the growth of MCF-7 tumors in mice. Animals
were treated on Days 13. 15, 17, 19, and 21 with 20 Â¿ig(TJ),50 ng (â€¢).or 75 jig
(O) of B3-LysPE40 i.v. The control group received mAb B3 alone (â€¢).Points,
mean; bars, SD.
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Fig. 4. Immunohistochemical localization of B3 antigen. Frozen sections of A431 tumor (.-I), MCF-7 tumor (fi) resected from nude mice, and a human colon
carcinoma (C). Bar, 10 jim. X 238.
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Fig. 5. Serum SCOT (-4), SGPT (B), alkaline phosphatase (C) of monkeys after receiving 10 (D), 30 (â€¢),50 (O), and 100 (A) Mg/kg of B3-PE. Blood samples were
obtained on Days -3, 1, 3, 5, 10, 21, and 29 of the study.
Table 1 Serum level ofBi-PE in monkeys
Dose(tig/kg)103050100Monkey12121212Day12
560
46172
166833625Serum
level1
Day5
21
12.7862384
178909806(ng/ml)3
Day527
5 13130
100294
384227
83
Â°Third dose omitted because of toxicity.
in the animals that received 10, 30, and 50 /ug/kg of B3-PE.
Bilirubin remained normal in these groups. There were no
significant changes in the other blood chemistries (electrolytes,
blood urea nitrogen, creatinine) or cell blood count. Serum
amylase levels remained normal. Urinalysis showed no evidence
of bladder injury during therapy. However, occult blood was
noted occasionally in the urine of female monkeys due to
menses contamination. There were no occult blood found in
the stool.
Monkeys that received 100 /ug/kg developed massive liver
failure. Both animals died on Day 5 of the study. Liver enzymes
were elevated more than 100-fold from pretreatment levels, and
serum bilirubin ranged from 4 to 5 mg/dl on Day 5. At ne
cropsy, the liver was found to be very pale in both animals.
Histological examination of the liver showed diffuse hepatic
necrosis characterized by cleared, vacuolated cytoplasm in most
hepatocytes with condensed, pyknotic nuclei and perivascular
acute inflammatory infiltrates. Histological examination re
vealed no significant abnormalities in the heart, kidney, trachea,
spleen, lymph node, pancreas, stomach, urinary bladder, or
lungs.
Blood samples were obtained approximately 10 min after
dosing on Days 1, 3, and 5. Serum levels of B3-PE were
measured by bioassay, and results from each individual monkey
are shown on Table 1. Results are consistent with the amount
of immunotoxin administered. The serum level of B3-PE in
creased after each dose. Monkeys that received 10, 30, and 50
Mg/kg on Days 1, 3, and 5 achieved serum levels as high as 27
ng/ml, 130 ng/ml, and 384 ng/ml by Day 5, respectively. These
animals had liver injury that was reversible, as shown by nor
malization of liver enzymes. The two monkeys that received
100 Mg/kg on Days 1 and 3 achieved blood levels as high as
909 and 806 ng/ml of B3-PE after the second dose. The third
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dose was omitted in this group due to toxicity. Plasma levels
obtained prior to necropsy were 227 and 83 ng/ml.
DISCUSSION
In the present study, monoclonal antibody B3 was linked to
native PE or LysPE40, a recombinant form of PE, and shown
to have a significant antitumor effect in nude mice bearing an
established human breast carcinoma, MCF-7. B3-PE was able
to cause substantial tumor regression and delay of growth at a
dose level of 1.5 Mgevery other day for 4 days. B3-LysPE40 at
a dose level of 75 ng every other day for 4 days caused complete
regression of MCF-7 tumor. We have previously shown that
both immunotoxins were capable of causing complete disap
pearance of A431 tumors in nude mice at a lower dose level.
Because both A431 and MCF-7 cells in vitro have a similar
ID50, 0.1 to 0.3 ng/ml for B3-PE and 1 to 4 ng/ml for B3-
LysPE40, this difference in tumor response in mice may be due
to the difference in the growth rate of the tumors in mice or
the ability of the immunotoxin to penetrate into the tumor (9).
A431 tumors grow very rapidly in mice, taking only 7 to 10
days to achieve 0.5 cm', while it takes approximately 4 wk for
MCF-7 tumors to achieve a similar volume. Because PE kills
cells by inhibiting protein synthesis, cells that are actively
growing may be more sensitive to these immunotoxins.
When compared with the reactivity of a human colon carci
noma specimen removed directly from a patient, the MCF-7
tumor and the A431 tumor grown in mice had a lower reactivity
with the B3 antibody as shown by immunohistochemical analy
sis. Since the intensity of staining of the colon tumor is typical
of many human carcinomas studies (8), we believe that similar
or greater antitumor effects can be achieved in patients with
tumors reactive to B3 antibody.
To determine if B3 linked to PE or PE40 could be developed
for use in humans, we next evaluated the toxicity of B3-PE in
Cynomolgus monkeys. B3-PE rather that B3-LysPE40 was
selected because B3-PE is about 10-fold more potent, and
limiting amounts of LysPE40 were available for preparation of
immunotoxin. Monkeys were chosen because the B3 antigen is
present in similar locations and at similar amounts in human
and monkey tissues. These locations are in glands of the stom
ach and epithelium of the bladder, trachea, and tonsils (8).
Based on these findings respiratory, gastrointestinal, or bladder
injury was anticipated. However, no specific B3 antigen-tar
geted toxicity was observed at the doses administered. Except
for liver toxicity, related to PE itself, no clinical signs of injury
or histological abnormalities in organs that express B3 antigen
were seen. Limiting toxicity was liver failure related to PE at
the 100-fig/kg dose level. This confirms our previous study with
another PE-containing immunotoxin, anti-Tac-PE, when ad
ministered to monkeys in preclinical studies; at doses of 66 ng/
kg every day for 7 days, liver damage was the major toxicity
observed.5 Because B3-LysPE40 is better tolerated than is B3-
' R. Kirkman, D. FiuGerald, and 1. Pastan, unpublished data.
PE, we anticipate that in monkeys and humans that therapeutic
levels can be achieved without significant liver toxicity. Previ
ously we described a method of preparing LysPE40 from the
bacterial culture medium (11). The toxin contained an OmpA
signal sequence to promote secretion. Recently, we have found
it is easier to purify LysPE40 from the periplasm where it
accumulates at much higher concentrations than in the medium.
When the OmpA signal sequence was removed, a large propor
tion of LysPE40 was found in the periplasm from which it
could be readily purified.
We conclude that monoclonal B3 when coupled to PE or
PE40 has strong antitumor activity in nude mice bearing xen-
ograft tumors that express B3 antigen. The similar reactivity of
mAb B3 with immunotoxin-sensitive MCF-7 and A431 tumors
and a human colon carcinoma sample makes us believe that a
similar effect can be achieved in patients. Toxicity studies in
monkeys demonstrate that therapeutic doses of B3-PE can be
delivered without injury to normal organs that express B3
antigen. These data indicate that immunotoxins composed of
B3 and PE or LysPE40 warrant further evaluation as antitumor
agents in cancer patients.
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